Ionis Pharmaceuticals, Inc. Forecasted to Post FY2026 Earnings of $1.09 Per Share (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Analysts at Leerink Partnrs boosted their FY2026 earnings per share (EPS) estimates for shares of Ionis Pharmaceuticals in a research note issued to investors on Tuesday, April 16th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings per share of $1.09 for the year, up from their prior forecast of $1.04. The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($4.00) per share. Leerink Partnrs also issued estimates for Ionis Pharmaceuticals’ FY2027 earnings at $1.56 EPS.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its earnings results on Wednesday, February 21st. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.72. The business had revenue of $325.00 million for the quarter, compared to analyst estimates of $176.01 million. Ionis Pharmaceuticals had a negative return on equity of 90.29% and a negative net margin of 46.32%. The business’s quarterly revenue was up 113.8% on a year-over-year basis. During the same quarter last year, the company earned ($0.37) EPS.

Several other research firms have also commented on IONS. Bank of America raised Ionis Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $52.00 to $62.00 in a research report on Tuesday, January 2nd. JPMorgan Chase & Co. increased their price target on shares of Ionis Pharmaceuticals from $52.00 to $55.00 and gave the stock a “neutral” rating in a report on Thursday, February 1st. StockNews.com raised shares of Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 24th. Oppenheimer increased their price target on shares of Ionis Pharmaceuticals from $72.00 to $75.00 and gave the stock an “outperform” rating in a report on Tuesday, April 9th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $60.00 target price on shares of Ionis Pharmaceuticals in a report on Tuesday, April 9th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Ionis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.08.

Ionis Pharmaceuticals Trading Down 1.5 %

IONS opened at $40.91 on Wednesday. The firm has a market cap of $5.96 billion, a price-to-earnings ratio of -15.98 and a beta of 0.39. Ionis Pharmaceuticals has a 52 week low of $34.32 and a 52 week high of $54.44. The business’s 50 day moving average is $44.25 and its two-hundred day moving average is $47.35. The company has a quick ratio of 5.83, a current ratio of 5.90 and a debt-to-equity ratio of 3.18.

Insider Buying and Selling at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, EVP Patrick R. O’neil sold 6,450 shares of Ionis Pharmaceuticals stock in a transaction on Thursday, January 25th. The shares were sold at an average price of $51.75, for a total value of $333,787.50. Following the transaction, the executive vice president now owns 46,802 shares in the company, valued at approximately $2,422,003.50. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, CEO Brett P. Monia sold 23,501 shares of Ionis Pharmaceuticals stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $49.37, for a total transaction of $1,160,244.37. Following the sale, the chief executive officer now owns 174,138 shares of the company’s stock, valued at approximately $8,597,193.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Patrick R. O’neil sold 6,450 shares of Ionis Pharmaceuticals stock in a transaction on Thursday, January 25th. The stock was sold at an average price of $51.75, for a total transaction of $333,787.50. Following the sale, the executive vice president now directly owns 46,802 shares in the company, valued at approximately $2,422,003.50. The disclosure for this sale can be found here. Insiders have sold a total of 51,434 shares of company stock worth $2,556,127 in the last quarter. 2.65% of the stock is owned by insiders.

Institutional Investors Weigh In On Ionis Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Ionis Pharmaceuticals by 5.0% in the 3rd quarter. Vanguard Group Inc. now owns 12,806,023 shares of the company’s stock worth $566,411,000 after purchasing an additional 605,747 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its position in shares of Ionis Pharmaceuticals by 4.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 11,678,259 shares of the company’s stock worth $441,088,000 after purchasing an additional 521,564 shares during the last quarter. Clearbridge Investments LLC increased its position in shares of Ionis Pharmaceuticals by 10.1% in the 1st quarter. Clearbridge Investments LLC now owns 6,476,033 shares of the company’s stock worth $239,872,000 after purchasing an additional 593,051 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Ionis Pharmaceuticals by 162.2% in the 4th quarter. Wellington Management Group LLP now owns 4,616,978 shares of the company’s stock worth $233,573,000 after purchasing an additional 2,856,353 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Ionis Pharmaceuticals by 13.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,255,074 shares of the company’s stock worth $215,265,000 after purchasing an additional 497,077 shares during the last quarter. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.